A phase I trial of APX 3330 for the treatment of pancreatic cancer

Trial Profile

A phase I trial of APX 3330 for the treatment of pancreatic cancer

Planning
Phase of Trial: Phase I

Latest Information Update: 01 Mar 2017

At a glance

  • Drugs APX 3330 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Apexian Pharmaceuticals
  • Most Recent Events

    • 01 Mar 2017 According to an ApeX Therapeutics media release, the US FDA has granted authorization to initiate this trial.
    • 31 Oct 2016 According to an ApeX Therapeutics media release, company announced acceptance by the U.S. Food and Drug Administration for review of an Investigational New Drug Application to evaluate the tolerability and anti-tumor effects of APX3330.
    • 20 Jul 2016 According to an ApeX Therapeutics media release, the US FDA has accepted the IND application for review for this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top